1月24日，专注于开发创新型偶联药物的临床阶段生物科技公司苏州宜联生物医药有限公司（以下简称“宜联生物”） ...

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs ...

Fmoc-Val-Cit-PAB 是一种可降解 (cleavable) 的抗体偶联活性分子 (ADC) 常用 linker。 Fmoc-Val-Cit-PAB作为一种在药物设计中占据核心地位的分子，近年来在抗体偶联药物（Antibody-Drug Conjugates，简称ADC）领域受到了广泛关注。它是一种可降解（cleavable）的异源性接头（linker ...

DS-3939 is designed using Daiichi Sankyo’s proprietary DXd ADC technology, which employs a combination of tetrapeptide-based cleavable linkers and topoisomerase I inhibitor payloads to deliver ...

MUNICH, Germany I January 30, 2025 I Tubulis announced today that its second drug candidate, TUB-030, has entered clinical evaluation with successful dosing ...

The ADC targets 5T4, an oncofetal antigen expressed in a broad range of solid tumors. The program was developed using Tubulis’ proprietary Tubutecan linker-payload platform, which enables ...

Pancreatic cancer is one of the deadliest of all cancers. Only 12% of men diagnosed with pancreatic cancer are alive five years after diagnosis; for women it is 14%.

Antibody Drug Conjugates Market Market Growth Fueled by Advancements in ADC Technology, Increased Demand for Targeted Cancer Therapies, and ...